These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9819297)

  • 1. Phosphodiesterase type 4 inhibitors, but not glucocorticoids, are more potent in suppression of cytokine secretion by mononuclear cells from atopic than nonatopic donors.
    Crocker IC; Ohia SE; Church MK; Townley RG
    J Allergy Clin Immunol; 1998 Nov; 102(5):797-804. PubMed ID: 9819297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
    Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
    J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccharide-stimulated human peripheral blood mononuclear cells.
    Yoshimura T; Kurita C; Nagao T; Usami E; Nakao T; Watanabe S; Kobayashi J; Yamazaki F; Tanaka H; Nagai H
    Gen Pharmacol; 1997 Oct; 29(4):633-8. PubMed ID: 9352314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study.
    Gantner F; Tenor H; Gekeler V; Schudt C; Wendel A; Hatzelmann A
    J Allergy Clin Immunol; 1997 Oct; 100(4):527-35. PubMed ID: 9338548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis.
    Banner KH; Roberts NM; Page CP
    Br J Pharmacol; 1995 Dec; 116(8):3169-74. PubMed ID: 8719792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells.
    Crocker IC; Townley RG; Khan MM
    Immunopharmacology; 1996 Mar; 31(2-3):223-35. PubMed ID: 8861748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
    Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM; Barnes PJ; Giembycz MA
    Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice.
    Liang L; Beshay E; Prud'homme GJ
    Diabetes; 1998 Apr; 47(4):570-5. PubMed ID: 9568689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.
    Draheim R; Egerland U; Rundfeldt C
    J Pharmacol Exp Ther; 2004 Feb; 308(2):555-63. PubMed ID: 14610230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of anti-CD3-induced interleukin-4 and interleukin-5 release from splenocytes of Mesocestoides corti-infected BALB/c mice by phosphodiesterase 4 inhibitors.
    Souness JE; Houghton C; Sardar N; Withnall MT
    Biochem Pharmacol; 1999 Sep; 58(6):991-9. PubMed ID: 10509751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity.
    Shafiee-Nick R; Pyne NJ; Furman BL
    Br J Pharmacol; 1995 Aug; 115(8):1486-92. PubMed ID: 8564209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen-induced cytokine gene expression in peripheral blood mononuclear cells.
    Essayan DM; Huang SK; Kagey-Sobotka A; Lichtenstein LM
    Am J Respir Cell Mol Biol; 1995 Dec; 13(6):692-702. PubMed ID: 7576707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
    Seldon PM; Barnes PJ; Meja K; Giembycz MA
    Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effect of phosphodiesterase inhibitors on IL-13 release from peripheral blood mononuclear cells.
    Yoshida N; Shimizu Y; Kitaichi K; Hiramatsu K; Takeuchi M; Ito Y; Kume H; Yamaki K; Suzuki R; Shibata E; Hasegawa T; Takagi K
    Clin Exp Immunol; 2001 Dec; 126(3):384-9. PubMed ID: 11737051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation.
    Jimenez JL; Punzón C; Navarro J; Muñoz-Fernández MA; Fresno M
    J Pharmacol Exp Ther; 2001 Nov; 299(2):753-9. PubMed ID: 11602691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
    Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
    Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors.
    Martin-Chouly CA; Astier A; Jacob C; Pruniaux MP; Bertrand C; Lagente V
    Life Sci; 2004 Jul; 75(7):823-40. PubMed ID: 15183075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-TNF-alpha properties of new 9-benzyladenine derivatives with selective phosphodiesterase-4- inhibiting properties.
    Reimund JM; Raboisson P; Pinna G; Lugnier C; Bourguignon JJ; Muller CD
    Biochem Biophys Res Commun; 2001 Oct; 288(2):427-34. PubMed ID: 11606060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis.
    Foey AD; Field S; Ahmed S; Jain A; Feldmann M; Brennan FM; Williams R
    Arthritis Res Ther; 2003; 5(6):R317-28. PubMed ID: 14680506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.